APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine Conjugate

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaccine Conjugate Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchVaccine Conjugate Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Conjugate Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Vaccine Conjugate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Conjugate Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Conjugate Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Vaccine Conjugate market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaccine Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaccine Conjugate market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaccine Conjugate market include Bharat Biotech, Beijing Minhai Biotechnology, Beijing Xiangrui Biological Products, Chengdu Olymvax Biopharmaceuticals, GSK, Pfizer, CanSinoBIO, Royal (Wuxi) Bio-Pharmaceutical and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaccine Conjugate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine Conjugate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine Conjugate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaccine Conjugate market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaccine Conjugate Segment by Company

Bharat Biotech

Beijing Minhai Biotechnology

Beijing Xiangrui Biological Products

Chengdu Olymvax Biopharmaceuticals

GSK

Pfizer

CanSinoBIO

Royal (Wuxi) Bio-Pharmaceutical

Merck

Sanofi

Walvax Biotechnology

Zhifei Biologic

Vaccine Conjugate Segment by Type

Hib Vaccine

Pneumococcal Vaccine

Meningococcal Vaccine

Others

Vaccine Conjugate Segment by Application

Children

Adult

Vaccine Conjugate Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaccine Conjugate status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vaccine Conjugate market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine Conjugate significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine Conjugate competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Conjugate.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaccine Conjugate market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine Conjugate industry.

Chapter 3: Detailed analysis of Vaccine Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vaccine Conjugate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vaccine Conjugate in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine Conjugate Industry Trends Table 2. Vaccine Conjugate Industry Drivers Table 3. Vaccine Conjugate Industry Opportunities and Challenges Table 4. Vaccine Conjugate Industry Restraints Table 5. Global Vaccine Conjugate Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine Conjugate Revenue Share by Company (2021-2026) Table 7. Global Vaccine Conjugate Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Vaccine Conjugate Sales Volume Share by Company (2021-2026) Table 9. Global Vaccine Conjugate Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Vaccine Conjugate Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vaccine Conjugate Key Company Manufacturing Base & Headquarters Table 12. Global Vaccine Conjugate Company, Product Type & Application Table 13. Global Vaccine Conjugate Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaccine Conjugate by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hib Vaccine Table 18. Significant Companies of Pneumococcal Vaccine Table 19. Significant Companies of Meningococcal Vaccine Table 20. Significant Companies of Others Table 21. Global Vaccine Conjugate Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Vaccine Conjugate Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Vaccine Conjugate Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Vaccine Conjugate Sales Volume Share by Type (2021-2026) Table 25. Global Vaccine Conjugate Sales Volume Share by Type (2027-2032) Table 26. Global Vaccine Conjugate Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vaccine Conjugate Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Vaccine Conjugate Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Vaccine Conjugate Sales Value Share by Type (2021-2026) Table 30. Global Vaccine Conjugate Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Children Table 32. Significant Companies of Adult Table 33. Global Vaccine Conjugate Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Vaccine Conjugate Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Vaccine Conjugate Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Vaccine Conjugate Sales Volume Share by Application (2021-2026) Table 37. Global Vaccine Conjugate Sales Volume Share by Application (2027-2032) Table 38. Global Vaccine Conjugate Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Vaccine Conjugate Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Vaccine Conjugate Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Vaccine Conjugate Sales Value Share by Application (2021-2026) Table 42. Global Vaccine Conjugate Sales Value Share by Application (2027-2032) Table 43. Global Vaccine Conjugate Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Vaccine Conjugate Sales by Region (2021-2026) & (K Units) Table 45. Global Vaccine Conjugate Sales Market Share by Region (2021-2026) Table 46. Global Vaccine Conjugate Sales by Region (2027-2032) & (K Units) Table 47. Global Vaccine Conjugate Sales Market Share by Region (2027-2032) Table 48. Global Vaccine Conjugate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Vaccine Conjugate Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Vaccine Conjugate Sales Value Share by Region (2021-2026) Table 51. Global Vaccine Conjugate Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Vaccine Conjugate Sales Value Share by Region (2027-2032) Table 53. Global Vaccine Conjugate Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Vaccine Conjugate Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Vaccine Conjugate Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Vaccine Conjugate Sales by Country (2021-2026) & (K Units) Table 58. Global Vaccine Conjugate Sales Market Share by Country (2021-2026) Table 59. Global Vaccine Conjugate Sales by Country (2027-2032) & (K Units) Table 60. Global Vaccine Conjugate Sales Market Share by Country (2027-2032) Table 61. Global Vaccine Conjugate Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Vaccine Conjugate Sales Value Market Share by Country (2021-2026) Table 63. Global Vaccine Conjugate Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Vaccine Conjugate Sales Value Market Share by Country (2027-2032) Table 65. Bharat Biotech Company Information Table 66. Bharat Biotech Business Overview Table 67. Bharat Biotech Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bharat Biotech Vaccine Conjugate Product Portfolio Table 69. Bharat Biotech Recent Development Table 70. Beijing Minhai Biotechnology Company Information Table 71. Beijing Minhai Biotechnology Business Overview Table 72. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio Table 74. Beijing Minhai Biotechnology Recent Development Table 75. Beijing Xiangrui Biological Products Company Information Table 76. Beijing Xiangrui Biological Products Business Overview Table 77. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio Table 79. Beijing Xiangrui Biological Products Recent Development Table 80. Chengdu Olymvax Biopharmaceuticals Company Information Table 81. Chengdu Olymvax Biopharmaceuticals Business Overview Table 82. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio Table 84. Chengdu Olymvax Biopharmaceuticals Recent Development Table 85. GSK Company Information Table 86. GSK Business Overview Table 87. GSK Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. GSK Vaccine Conjugate Product Portfolio Table 89. GSK Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Pfizer Vaccine Conjugate Product Portfolio Table 94. Pfizer Recent Development Table 95. CanSinoBIO Company Information Table 96. CanSinoBIO Business Overview Table 97. CanSinoBIO Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. CanSinoBIO Vaccine Conjugate Product Portfolio Table 99. CanSinoBIO Recent Development Table 100. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 101. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 102. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio Table 104. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 105. Merck Company Information Table 106. Merck Business Overview Table 107. Merck Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Merck Vaccine Conjugate Product Portfolio Table 109. Merck Recent Development Table 110. Sanofi Company Information Table 111. Sanofi Business Overview Table 112. Sanofi Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Sanofi Vaccine Conjugate Product Portfolio Table 114. Sanofi Recent Development Table 115. Walvax Biotechnology Company Information Table 116. Walvax Biotechnology Business Overview Table 117. Walvax Biotechnology Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Walvax Biotechnology Vaccine Conjugate Product Portfolio Table 119. Walvax Biotechnology Recent Development Table 120. Zhifei Biologic Company Information Table 121. Zhifei Biologic Business Overview Table 122. Zhifei Biologic Vaccine Conjugate Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Zhifei Biologic Vaccine Conjugate Product Portfolio Table 124. Zhifei Biologic Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Vaccine Conjugate Distributors List Table 128. Vaccine Conjugate Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Vaccine Conjugate Product Image Figure 2. Global Vaccine Conjugate Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vaccine Conjugate Sales (2021-2032) & (K Units) Figure 5. Global Vaccine Conjugate Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Vaccine Conjugate Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hib Vaccine Image Figure 10. Pneumococcal Vaccine Image Figure 11. Meningococcal Vaccine Image Figure 12. Others Image Figure 13. Global Vaccine Conjugate Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Vaccine Conjugate Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Vaccine Conjugate Sales Volume Share by Type (2021-2032) Figure 16. Global Vaccine Conjugate Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Vaccine Conjugate Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Vaccine Conjugate Sales Value Share by Type (2021-2032) Figure 19. Children Image Figure 20. Adult Image Figure 21. Global Vaccine Conjugate Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Vaccine Conjugate Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Vaccine Conjugate Sales Volume Share by Application (2021-2032) Figure 24. Global Vaccine Conjugate Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Vaccine Conjugate Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Vaccine Conjugate Sales Value Share by Application (2021-2032) Figure 27. Global Vaccine Conjugate Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Vaccine Conjugate Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Vaccine Conjugate Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Vaccine Conjugate Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 32. North America Vaccine Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Vaccine Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Vaccine Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 38. South America Vaccine Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Vaccine Conjugate Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Vaccine Conjugate Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Vaccine Conjugate Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Vaccine Conjugate Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Vaccine Conjugate Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Pneumococcal Vaccine
  • Meningococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Bharat Biotech
  • Beijing Minhai Biotechnology
  • Beijing Xiangrui Biological Products
  • Chengdu Olymvax Biopharmaceuticals
  • GSK
  • Pfizer
  • CanSinoBIO
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck
  • Sanofi
  • Walvax Biotechnology
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaccine Conjugate Sales Value (2021-2032)
  4. 1.2.2 Global Vaccine Conjugate Sales Volume (2021-2032)
  5. 1.2.3 Global Vaccine Conjugate Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vaccine Conjugate Market Dynamics
  1. 2.1 Vaccine Conjugate Industry Trends
  2. 2.2 Vaccine Conjugate Industry Drivers
  3. 2.3 Vaccine Conjugate Industry Opportunities and Challenges
  4. 2.4 Vaccine Conjugate Industry Restraints
3 Vaccine Conjugate Market by Company
  1. 3.1 Global Vaccine Conjugate Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine Conjugate Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine Conjugate Sales Volume by Company (2021-2026)
  4. 3.4 Global Vaccine Conjugate Average Price by Company (2021-2026)
  5. 3.5 Global Vaccine Conjugate Company Ranking (2024-2026)
  6. 3.6 Global Vaccine Conjugate Company Manufacturing Base and Headquarters
  7. 3.7 Global Vaccine Conjugate Company Product Type and Application
  8. 3.8 Global Vaccine Conjugate Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vaccine Conjugate Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vaccine Conjugate Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vaccine Conjugate Market by Type
  1. 4.1 Vaccine Conjugate Type Introduction
  2. 4.1.1 Hib Vaccine
  3. 4.1.2 Pneumococcal Vaccine
  4. 4.1.3 Meningococcal Vaccine
  5. 4.1.4 Others
  6. 4.2 Global Vaccine Conjugate Sales Volume by Type
  7. 4.2.1 Global Vaccine Conjugate Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Vaccine Conjugate Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Vaccine Conjugate Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Vaccine Conjugate Sales Value by Type
  11. 4.3.1 Global Vaccine Conjugate Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Vaccine Conjugate Sales Value by Type (2021-2032)
  13. 4.3.3 Global Vaccine Conjugate Sales Value Share by Type (2021-2032)
5 Vaccine Conjugate Market by Application
  1. 5.1 Vaccine Conjugate Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Vaccine Conjugate Sales Volume by Application
  5. 5.2.1 Global Vaccine Conjugate Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine Conjugate Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Vaccine Conjugate Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Vaccine Conjugate Sales Value by Application
  9. 5.3.1 Global Vaccine Conjugate Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Vaccine Conjugate Sales Value by Application (2021-2032)
  11. 5.3.3 Global Vaccine Conjugate Sales Value Share by Application (2021-2032)
6 Vaccine Conjugate Regional Sales and Value Analysis
  1. 6.1 Global Vaccine Conjugate Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Conjugate Sales by Region (2021-2032)
  3. 6.2.1 Global Vaccine Conjugate Sales by Region: 2021-2026
  4. 6.2.2 Global Vaccine Conjugate Sales by Region (2027-2032)
  5. 6.3 Global Vaccine Conjugate Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vaccine Conjugate Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vaccine Conjugate Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vaccine Conjugate Sales Value by Region (2027-2032)
  9. 6.5 Global Vaccine Conjugate Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vaccine Conjugate Sales Value (2021-2032)
  12. 6.6.2 North America Vaccine Conjugate Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vaccine Conjugate Sales Value (2021-2032)
  15. 6.7.2 Europe Vaccine Conjugate Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vaccine Conjugate Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vaccine Conjugate Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vaccine Conjugate Sales Value (2021-2032)
  21. 6.9.2 South America Vaccine Conjugate Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vaccine Conjugate Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vaccine Conjugate Sales Value Share by Country, 2025 VS 2032
7 Vaccine Conjugate Country-level Sales and Value Analysis
  1. 7.1 Global Vaccine Conjugate Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine Conjugate Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vaccine Conjugate Sales by Country (2021-2032)
  4. 7.3.1 Global Vaccine Conjugate Sales by Country (2021-2026)
  5. 7.3.2 Global Vaccine Conjugate Sales by Country (2027-2032)
  6. 7.4 Global Vaccine Conjugate Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vaccine Conjugate Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vaccine Conjugate Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vaccine Conjugate Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vaccine Conjugate Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vaccine Conjugate Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bharat Biotech
  2. 8.1.1 Bharat Biotech Company Information
  3. 8.1.2 Bharat Biotech Business Overview
  4. 8.1.3 Bharat Biotech Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bharat Biotech Vaccine Conjugate Product Portfolio
  6. 8.1.5 Bharat Biotech Recent Developments
  7. 8.2 Beijing Minhai Biotechnology
  8. 8.2.1 Beijing Minhai Biotechnology Company Information
  9. 8.2.2 Beijing Minhai Biotechnology Business Overview
  10. 8.2.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolio
  12. 8.2.5 Beijing Minhai Biotechnology Recent Developments
  13. 8.3 Beijing Xiangrui Biological Products
  14. 8.3.1 Beijing Xiangrui Biological Products Company Information
  15. 8.3.2 Beijing Xiangrui Biological Products Business Overview
  16. 8.3.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolio
  18. 8.3.5 Beijing Xiangrui Biological Products Recent Developments
  19. 8.4 Chengdu Olymvax Biopharmaceuticals
  20. 8.4.1 Chengdu Olymvax Biopharmaceuticals Company Information
  21. 8.4.2 Chengdu Olymvax Biopharmaceuticals Business Overview
  22. 8.4.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolio
  24. 8.4.5 Chengdu Olymvax Biopharmaceuticals Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GSK Vaccine Conjugate Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Vaccine Conjugate Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 CanSinoBIO
  38. 8.7.1 CanSinoBIO Company Information
  39. 8.7.2 CanSinoBIO Business Overview
  40. 8.7.3 CanSinoBIO Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CanSinoBIO Vaccine Conjugate Product Portfolio
  42. 8.7.5 CanSinoBIO Recent Developments
  43. 8.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 8.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 8.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 8.8.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolio
  48. 8.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Vaccine Conjugate Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Vaccine Conjugate Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Walvax Biotechnology
  62. 8.11.1 Walvax Biotechnology Company Information
  63. 8.11.2 Walvax Biotechnology Business Overview
  64. 8.11.3 Walvax Biotechnology Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Walvax Biotechnology Vaccine Conjugate Product Portfolio
  66. 8.11.5 Walvax Biotechnology Recent Developments
  67. 8.12 Zhifei Biologic
  68. 8.12.1 Zhifei Biologic Company Information
  69. 8.12.2 Zhifei Biologic Business Overview
  70. 8.12.3 Zhifei Biologic Vaccine Conjugate Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhifei Biologic Vaccine Conjugate Product Portfolio
  72. 8.12.5 Zhifei Biologic Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaccine Conjugate Value Chain Analysis
  2. 9.1.1 Vaccine Conjugate Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaccine Conjugate Sales Mode & Process
  6. 9.2 Vaccine Conjugate Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaccine Conjugate Distributors
  9. 9.2.3 Vaccine Conjugate Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst